The stock is currently selling less than 2 tenths of a penny and 2 billion more shares are looming. The company has not grown in years, and the management is not the best, so obviously this is not a good stock. However, stem cell technology should have a major impact in coming years. Cord Blood America, Inc. provides private cord blood and cord tissue stem cell storage services to families primarily in the United States,. Its services include the collection of materials, physician and customer support, transportation, and comprehensive testing. On June 25, 2014 Cord Blood America, Inc. "Company"), announced the launch of a new service offering for the isolation and expansion of mesenchymal stem cells through its wholly owned subsidiary CorCell Companies, Inc.(CorCell). This service was researched and developed in CorCell's laboratory and offers expecting parents an additional stem cell banking option. Recently they settled a lawsuit with their creditors, and are trying to pay off the debt as soon as they can. It appears CBAI is trying to improve. In conclusion, currently CBAI is not a good stock, but at less than 2 tenths of a penny, the risk is worth taking . The Company's past performance is not necessarily indicative of its future performance, however any real growth will be long term.
